歌礼制药－Ｂ(01672.HK)合作夥伴治疗脂肪性肝炎药物临床试验取得积极期中数据

AAFN2022-11-04

歌礼制药－Ｂ公布，其战略合作夥伴Sagimet Biosciences宣布，脂肪酸合成酶(FASN)抑制剂ASC40 (Denifanstat)治疗非酒精性脂肪性肝炎(NASH)患者2b期临床试验(FASCINATE-2)取得积极期中数据。数据显示，NASH各项关键标志物有统计学意义上的显着减少，包括肝脏脂肪含量、炎症和纤维化标志物，这进一步验证早期研究中观察到的结果。牛津大学访问学者、...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2280523375?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2022-11-04 08:59","share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","id":"2280523375","market":"us","top_or_hot":-1,"title":"歌礼制药－Ｂ(01672.HK)合作夥伴治疗脂肪性肝炎药物临床试验取得积极期中数据","media":"AAFN","content":"<div>\n<p>歌礼制药－Ｂ  公布，其战略合作夥伴Sagimet Biosciences宣布，脂肪酸合成酶(FASN)抑制剂ASC40 (Denifanstat)治疗非酒精性脂肪性肝炎(NASH)患者2b期临床试验(FASCINATE-2)取得积极期中数据。数据显示，NASH各项关键标志物有统计学意义上的显着减少，包括肝脏脂肪含量、炎症和纤维化标志物，这进一步验证早期研究中观察到的结果。牛津大学访问学者、...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1224144&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">网页链接</a>\n\n</div>\n","source":"aastocks","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>歌礼制药－Ｂ(01672.HK)合作夥伴治疗脂肪性肝炎药物临床试验取得积极期中数据</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n歌礼制药－Ｂ(01672.HK)合作夥伴治疗脂肪性肝炎药物临床试验取得积极期中数据\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-11-04 08:59 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1224144&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>歌礼制药－Ｂ  公布，其战略合作夥伴Sagimet Biosciences宣布，脂肪酸合成酶(FASN)抑制剂ASC40 (Denifanstat)治疗非酒精性脂肪性肝炎(NASH)患者2b期临床试验(FASCINATE-2)取得积极期中数据。数据显示，NASH各项关键标志物有统计学意义上的显着减少，包括肝脏脂肪含量、炎症和纤维化标志物，这进一步验证早期研究中观察到的结果。牛津大学访问学者、...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1224144&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1224144&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","article_id":"2280523375","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2280523375","pubTimestamp":1667523592,"columns":[],"sourceInfo":{"source_id":"aastocks","name":"阿思达克财经"},"weMediaInfo":null,"summary":"歌礼制药－Ｂ  公布，其战略合作夥伴Sagimet Biosciences宣布，脂肪酸合成酶抑制剂ASC40 治疗非酒精性脂肪性肝炎患者2b期临床试验取得积极期中数据。数据显示，NASH各项关键标志物有统计学意义上的显着减少，包括肝脏脂肪含量、炎症和纤维化标志物，这进一步验证早期研究中观察到的结果。牛津大学访问学者、Pinnacle研究中心医学主任Stephen Harrison将於11月4至8日在美国华盛顿特区举办的美国肝病研究协会年会上就该研究的期中数据要点做口头报告。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1574":"生物医药B类股","BK1515":"抗疫概念","01672":"歌礼制药-B","BK1161":"生物科技"},"translate_title":"Golly Pharmaceutical-B (01672. HK) partner's clinical trial of drugs for treating steatohepatitis obtained positive mid-term data","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":0.9,"NASH":1},"content_text":"歌礼制药－Ｂ  公布，其战略合作夥伴Sagimet Biosciences宣布，脂肪酸合成酶(FASN)抑制剂ASC40 (Denifanstat)治疗非酒精性脂肪性肝炎(NASH)患者2b期临床试验(FASCINATE-2)取得积极期中数据。数据显示，NASH各项关键标志物有统计学意义上的显着减少，包括肝脏脂肪含量、炎症和纤维化标志物，这进一步验证早期研究中观察到的结果。牛津大学访问学者、Pinnacle研究中心医学主任Stephen Harrison将於11月4至8日在美国华盛顿特区举办的美国肝病研究协会(AASLD)年会上就该研究的期中数据要点做口头报告。(jl/k)~阿思达克财经新闻网址: www.aastocks.com","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2280523375","isCrawlerRequest":true}